Cairo Pharmaceuticals results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit171 millionEGP
Total assets1.74 billionEGP
Shareholders' equity850 millionEGP
Operating cash flow80.71 millionEGP
In short
- Cairo Pharmaceuticals's net profit for Q2 2025 was about 171 million EGP.
- Total assets at the end of Q2 2025 were about 1.74 billion EGP, and shareholders' equity about 850 million EGP.
- Operating cash flow for Q2 2025 was positive at 80.71 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit171 million——
Gross profit293 million——
Total assets1.74 billion——
Total liabilities886 million——
Shareholders' equity850 million——
Total liabilities and equity1.74 billion——
Operating cash flow80.71 million——
Investing cash flow-34.29 million——
Financing cash flow-116 million——
Net change in cash-69.23 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy